Koers Teva Pharmaceutical Industries Limited OTC Markets
Aandelen
TEVJF
IL0006290147
Farmaceutische producten
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
18 USD | +7,78% | +7,78% | +108,82% |
Omzet 2024 * | 16 mld. 14,94 mld. | Omzet 2025 * | 16,62 mld. 15,53 mld. | Marktkapitalisatie | 19,44 mld. 18,15 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 809 mln. 756 mln. | Nettowinst (verlies) 2025 * | 1,38 mld. 1,28 mld. | EV/omzet 2024 * | 2,15 x |
Nettoschuld 2024 * | 14,98 mld. 13,99 mld. | Nettoschuld 2025 * | 12,44 mld. 11,62 mld. | EV/omzet 2025 * | 1,92 x |
K/w-verhouding 2024 * |
17,8
x | K/w-verhouding 2025 * |
12,3
x | Werknemers | 35.737 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 90,92% |
Recentste transcriptie over Teva Pharmaceutical Industries Limited
1 dag | +7,78% | ||
1 week | +7,78% | ||
Lopende maand | +20,64% | ||
1 maand | +53,19% | ||
3 maanden | +36,36% | ||
6 maanden | +108,82% | ||
Lopend jaar | +108,82% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Richard Francis
CEO | Chief Executive Officer | 55 | 01-01-23 |
Eli Kalif
DFI | Director of Finance/CFO | 51 | 22-12-19 |
Kathleen Veit
CMP | Compliance Officer | - | 01-01-10 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Gerald Lieberman
BRD | Director/Board Member | 77 | 01-09-15 |
Janet Vergis
BRD | Director/Board Member | 59 | 09-06-20 |
Sol Barer
CHM | Chairman | 76 | 01-01-15 |
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+42,49% | 630 mld. | |
-7,15% | 350 mld. | |
+18,77% | 328 mld. | |
+8,79% | 298 mld. | |
+18,06% | 246 mld. | |
+0,65% | 225 mld. | |
+10,89% | 218 mld. | |
+3,68% | 160 mld. | |
-4,38% | 156 mld. |
- Beurs
- Aandelen
- Koers TEVA
- Koers TEVJF